 Shares of Enveric Biosciences Inc. doubled in very heavy volume in midday trading Wednesday, after the Florida-based biotechnology company focused on cannabinoid-based treatments and cancer treatments said it acquired a perpetual license from Diverse Biotech for novel molecules for developing cancer treatments. Trading volume ballooned to 214.6 million shares, compared with the full-day average of about 2.4 million shares over the past 30 days. 